{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T02:48:33Z","timestamp":1717987713070},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1331\/japha.2015.15508","type":"journal-article","created":{"date-parts":[[2015,2,6]],"date-time":"2015-02-06T15:30:23Z","timestamp":1423236623000},"page":"e72-e86","source":"Crossref","is-referenced-by-count":7,"title":["Hepatitis C therapy: Looking toward interferon-sparing regimens"],"prefix":"10.1016","volume":"55","author":[{"given":"Trang H.","family":"Au","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Destache","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renuga","family":"Vivekanandan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1331\/JAPhA.2015.15508_bb0010","unstructured":"Hepatitis C. Fact Sheet No. 164. Geneva, Switzerland: World Health Organization http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/ Accessed July 24, 2014."},{"issue":"10","key":"10.1331\/JAPhA.2015.15508_bb0015","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1331\/JAPhA.2015.15508_bb0020","unstructured":"Recommendations for testing, managing, and treating hepatitis C. American Association for the Study of Liver Diseases and Infectious Diseases Society of America. http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/. Accessed July 24, 2014."},{"key":"10.1331\/JAPhA.2015.15508_bb0025","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/0003-4819-156-4-201202210-00004","article-title":"The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007","volume":"156","author":"Ly","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1331\/JAPhA.2015.15508_bb0030","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1093\/cid\/cis367","article-title":"HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms","volume":"55","author":"Taylor","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1331\/JAPhA.2015.15508_bb0035","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/cid\/cis393","article-title":"Evolving epidemiology of hepatitis C virus in the United States","volume":"55","author":"Klevens","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1331\/JAPhA.2015.15508_bb0040","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/jamainternmed.2013.12505","article-title":"The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry","volume":"174","author":"McCombs","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1331\/JAPhA.2015.15508_bb0045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5501\/wjv.v2.i1.6","article-title":"Hepatitis C virus resistance to new specifically targeted antiviral therapy: a public health perspective","volume":"2","author":"Salvatierra","year":"2013","journal-title":"World J Virol"},{"key":"10.1331\/JAPhA.2015.15508_bb0050","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"10.1331\/JAPhA.2015.15508_bb0055","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.gastro.2010.04.013","article-title":"Interleukin-28B polymorphism improves viral kinetics and is the strongest pre-treatment predictor of sustained virologic response in hepatitis C virus","volume":"139","author":"Thompson","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1331\/JAPhA.2015.15508_bb0060","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/MCG.0b013e3181e12c09","article-title":"Direct economic burden of chronic hepatitis C virus in a United States managed care population","volume":"45","author":"Davis","year":"2011","journal-title":"J Clin Gastroenterol"},{"issue":"21","key":"10.1331\/JAPhA.2015.15508_bb0065","doi-asserted-by":"crossref","first-page":"6457","DOI":"10.3748\/wjg.v20.i21.6457","article-title":"Virus-related liver cirrhosis: molecular basis and therapeutic options","volume":"20","author":"Lin","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1331\/JAPhA.2015.15508_bb0070","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/jac\/dkg137","article-title":"The mechanisms that control intracellular penetration of the HIV protease inhibitors","volume":"51","author":"Hoggard","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1331\/JAPhA.2015.15508_bb0075","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.3748\/wjg.v20.i13.3457","article-title":"How hepatitis C virus invades hepatocytes: the mystery of viral entry","volume":"20","author":"Zhu","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1331\/JAPhA.2015.15508_bb0080","doi-asserted-by":"crossref","first-page":"342","DOI":"10.4254\/wjh.v4.i12.342","article-title":"Hepatitis C virus-related hepatocellular carcinoma: an insight into molecular mechanisms and therapeutic strategies","volume":"4","author":"Selimovic","year":"2012","journal-title":"World J Hepatol"},{"key":"10.1331\/JAPhA.2015.15508_bb0085","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4103\/0974-777X.52979","article-title":"Association between hepatitis C and hepatocellular carcinoma","volume":"1","author":"Andrade","year":"2009","journal-title":"J Glob Infect Dis"},{"key":"10.1331\/JAPhA.2015.15508_bb0090","unstructured":"Hepatitis C FAQs for health professionals. Centers for Disease Control and Prevention. www.cdc.gov\/hepatitis\/HCV\/HCVfaq.htm. Accessed July 31, 2014."},{"key":"10.1331\/JAPhA.2015.15508_bb0095","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0016-5085(03)00668-1","article-title":"Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance","volume":"125","author":"Gerlach","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1331\/JAPhA.2015.15508_bb0100","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/j.1365-2036.2011.04861.x","article-title":"The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases","volume":"34","author":"Sebastinani","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1331\/JAPhA.2015.15508_bb0105","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1111\/j.1572-0241.2002.06038.x","article-title":"Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection [abstract]","volume":"97","author":"Regev","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1331\/JAPhA.2015.15508_bb0110","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2036.2009.03927.x","article-title":"Review article: investigational agents for chronic hepatitis C","volume":"29","author":"Thompson","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1331\/JAPhA.2015.15508_bb0115","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1055\/s-2004-832942","article-title":"Alcohol and hepatitis C","volume":"24","author":"Safdar","year":"2004","journal-title":"Semin Liver Dis"},{"key":"10.1331\/JAPhA.2015.15508_bb0120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.dld.2008.05.009","article-title":"Alcohol and viral hepatitis: a mini-review","volume":"41","author":"Gitto","year":"2009","journal-title":"Dig Liver Dis"},{"key":"10.1331\/JAPhA.2015.15508_bb0125","series-title":"Pegasys [product labeling]","year":"2002"},{"key":"10.1331\/JAPhA.2015.15508_bb0130","series-title":"Peg-Intron [product labeling]","year":"2001"},{"key":"10.1331\/JAPhA.2015.15508_bb0135","series-title":"Copegus [product labeling]","year":"2011"},{"key":"10.1331\/JAPhA.2015.15508_bb0140","series-title":"Rebetol [product labeling]","year":"2013"},{"key":"10.1331\/JAPhA.2015.15508_bb0145","series-title":"Victrelis [product labeling]","year":"2011"},{"key":"10.1331\/JAPhA.2015.15508_bb0150","series-title":"Incivek [product labeling]","year":"2013"},{"key":"10.1331\/JAPhA.2015.15508_bb0155","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1331\/JAPhA.2015.15508_bb0160","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2012.05.011","article-title":"Factors that predict response of patients with hepatitis C virus infection to boceprevir","volume":"143","author":"Poordad","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1331\/JAPhA.2015.15508_bb0165","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1111\/jvh.12237","article-title":"Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score","volume":"2","author":"Virlogeux","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1331\/JAPhA.2015.15508_bb0170","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.antiviral.2014.02.019","article-title":"Telaprevir or boceprevir-based therapy for chronic hepatitis C infection: development of resistance-associated variants in treatment failure","volume":"105","author":"Macartney","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1331\/JAPhA.2015.15508_bb0175","series-title":"Olysio [product labeling]","year":"2013"},{"key":"10.1331\/JAPhA.2015.15508_bb0180","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2147\/TCRM.S50170","article-title":"New treatments for genotype 1 chronic hepatitis C\u2014focus on simeprevir","volume":"10","author":"Kanda","year":"2014","journal-title":"Ther Clin Risk Manag"},{"key":"10.1331\/JAPhA.2015.15508_bb0185","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","article-title":"Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial","volume":"146","author":"Forns","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1331\/JAPhA.2015.15508_bb0190","series-title":"Sovaldi [product labeling]","year":"2013"},{"key":"10.1331\/JAPhA.2015.15508_bb0195","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1331\/JAPhA.2015.15508_bb0200","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1331\/JAPhA.2015.15508_bb0205","article-title":"Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial","author":"Zeuzem","year":"2013"},{"key":"10.1331\/JAPhA.2015.15508_bb0210","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1001\/jama.2014.5277","article-title":"WHO issues guidelines on HCV amid drug cost controversy","volume":"311","author":"Slomski","year":"2014","journal-title":"JAMA"},{"issue":"6","key":"10.1331\/JAPhA.2015.15508_bb0215","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/apt.12871","article-title":"Cost-effectiveness analysis of sofosbuvir plus peginterferon\/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection","volume":"40","author":"Saab","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1331\/JAPhA.2015.15508_bb0220","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/apt.12823","article-title":"Letter: estimating the cost-neutral price of sofosbuvir-based triple therapy for the treatment of na\u043fve patients with genotype 1 HCV infection in Italy","volume":"40","author":"Messori","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1331\/JAPhA.2015.15508_bb0225","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/cid\/cis1206","article-title":"Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection","volume":"56","author":"Fierer","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1331\/JAPhA.2015.15508_bb0230","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.2014.7734","article-title":"Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection","volume":"312","author":"Sulkowski","year":"2014","journal-title":"JAMA"},{"issue":"9956","key":"10.1331\/JAPhA.2015.15508_bb0235","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1331\/JAPhA.2015.15508_bb0240","unstructured":"FDA approves first combination pill to treat hepatitis C [news release]. Silver Spring, MD: U.S. Food and Drug Administration; October 10, 2014. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm418365.htm Accessed November 1, 2014."},{"key":"10.1331\/JAPhA.2015.15508_bb0245","series-title":"Harvoni [product labeling]","year":"2014"},{"key":"10.1331\/JAPhA.2015.15508_bb0250","unstructured":"Olysio (simeprevir) gains additional FDA approval as once-daily, all-oral interferon- and ribavirin-free treatment option in combination with sofosbuvir for adults with genotype 1 chronic hepatitis C infection [news release]. November 5, 2014. http:\/\/www.jnj.com\/news\/all\/OLYSIO-simeprevir-Gains-Additional-FDA-Approval-as-Once-Daily-All-Oral-Interferon-and-Ribavirin-Free-Treatment-Option-in-Combination-with-Sofosbuvir-for-Adults-with-Genotype-1-Chronic-Hepatitis-C-Infection. Accessed January 25, 2015."},{"key":"10.1331\/JAPhA.2015.15508_bb0255","series-title":"Viekira Pak [package insert]","year":"2014"},{"key":"10.1331\/JAPhA.2015.15508_bb0260","unstructured":"AbbVie receives U.S. FDA approval of Viekira Pak (ombitasvir\/paritaprevir\/ritonavir tablets; dasabuvir tablets) for the treatment of chronic genotype 1 hepatitis C [press release]. December 19, 2014. http:\/\/abbvie.mediaroom.com\/2014-12-19-AbbVie-Receives-U-S-FDA-Approval-of-VIEKIRA-PAK-Ombitasvir-Paritaprevir-Ritonavir-Tablets-Dasabuvir-Tablets-for-the-Treatment-of-Chronic-Genotype-1-Hepatitis-C. Accessed January 25, 2015."},{"key":"10.1331\/JAPhA.2015.15508_bb0265","unstructured":"Vertex to stop selling telaprevir in U.S. by October 2014, but will not stop selling it in Canada [news release]. http:\/\/www.catie.ca\/en\/news\/hepcinfo-updates\/2014-08-26. Accessed January 25, 2105."},{"key":"10.1331\/JAPhA.2015.15508_bb0270","unstructured":"A phase 3 study of a daclatasvir\/asunaprevir\/BMS-791325 fixed dose combination (FDC) in subjects with chronic hepatitis C genotype 1 (UNITY 4). NCT02170727. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02170727. Accessed January 25, 2015."},{"key":"10.1331\/JAPhA.2015.15508_bb0275","unstructured":"Grazoprevir (MK-5172) and elbasvir (MK-8742) combination for chronic hepatitis C virus (HCV) genotypes 1, 4, and 6 (MK-5172\u2013065). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02252016. Accessed January 25, 2015."}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319115300509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319115300509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T14:12:19Z","timestamp":1566310339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319115300509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S1544319115300509"],"URL":"https:\/\/doi.org\/10.1331\/japha.2015.15508","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}